Table 4.
Late adverse events in the two groups n (%)
| Late adverse event | NDP group | DDP group | χ2 | P value |
| Late esophageal injury | ||||
| 0 | 18 (52.9) | 13 (38.2) | ||
| I | 10 (29.4) | 12 (35.3) | ||
| II | 4 (11.8) | 5 (14.7) | 2.299 | 0.681 |
| III | 2 (5.9) | 3 (8.8) | ||
| IV | 0 (0) | 1 (2.9) | ||
| Late lung injury | ||||
| 0 | 24 (70.6) | 20 (58.8) | ||
| I | 7 (20.6) | 8 (23.5) | ||
| II | 2 (5.9) | 4 (11.8) | 1.43 | 0.698 |
| III | 1 (2.9) | 2 (5.9) | ||
| IV | 0 (0) | 0 (0) | ||
NDP: Nedaplatin; DDP: Cisplatin.